Proprotein convertases (PCs) are Ca 2 + -dependent serine proteases of the subtilisin/kexin family which are known specifically to cleave propeptide and proprotein substrates at the C-terminal of R-X-(K/R)-R↓ to generate the relevant biologically active peptides. PCs are initially synthesized as enzymically inactive proenzyme forms where the prosegments play an important inhibitory role to the respective enzymes. Here we investigated whether synthetic peptides derived from the pro-region could also represent specific and potent inhibitors. Based upon sequence alignment, secondary structure analysis and hydrophilicity plot, a number of peptides ranging from 8 to 33 residues were selected. These included segments encompassing residues 55-62, 50-62, 39-62, 50-83, 55-83, 64-83 and 74-83 in the pro-mouse PC1/3 sequence and residues 54-62, 48-62 and 39-62 of the prohuman furin sequence. All peptides were prepared by solidphase FastMoc chemistry, purified by reversed-phase HPLC and characterized by MS and amino acid analysis. These peptides were tested in vitro for inhibitory activity towards recombinant mouse PC1/3 and human furin. Progress-curve and end-time kinetic analysis demonstrated that a number of these peptides, particularly those containing both the primary and the secondary processing sites, displayed strong inhibition of both enzymes with inhibition constants (K i ) in the high nanomolar range. Unlike the whole propeptide, these small synthetic peptide inhibitors exhibited either true competitive or mixed competitive inhibition, depending on the sequence. Our data revealed further the critical role of the last two basic amino acid residues (e.g. Lys 82 -Arg 83 for the mouse PC1/3 sequence) of the prodomain in imparting a strong anti-convertase activity. The study also establishes the inhibitory potential of certain regions contained within the prosegment of the two convertases.
INTRODUCTION
A large variety of proteins are synthesized as precursors in the form of pre-proproteins. Whereas the presequences usually act as signal peptides for transport within the endoplasmic reticulum, thereby directing these proteins into the secretory pathway, the prosequences may serve different functions. For numerous proteolytic enzymes, it has been found that they act as intramolecular chaperone by catalysing the protein-folding process of, for example, cysteine and serine proteases [1, 2] . In addition, prosequences may also serve in many cases to regulate the activity of their associated enzymes, as their removal through proteolytic cleavages is a prerequisite to excise the fully enzymically active enzymes. This was described initially in the middle of the 19th century for the aspartyl protease pepsin and later on for a variety of other enzymes belonging to various classes. In fact the prosegment has been shown to be a potent and specific inhibitor of its associated protease. This has been demonstrated with cathepsins B and L [3, 4] , papain [5] , subtilisin [6, 7] , pepsin [8] and stromelysin [9] . This unique property of the prosegment can thus be seen as an additional strategy to regulate enzymic activity in delaying its onset until the moment when the enzyme needs to be fully functional.
All the seven known members of the family of kexin/subtilisinlike endopeptidases, namely proprotein convertase (PC) 1/3, Abbreviations used: PC, proprotein convertase; mPC, mouse PC1/3; Fmoc, fluoren-9-ylmethoxycarbonyl; Pmc, 2,2,5,7,8-pentamethylchroman-6-sulphonyl; pGlu, pyroglutamic acid; MCA, 4-methylcoumaryl-7-amide; RP-HPLC, reversed-phase HPLC; MALDI-TOF, matrix-assisted laser-desorption ionization-time-of-flight; hfurin, human furin; pro-PTH, proparathyroid hormone; QFS-8, (Abz-Gly-Ser-Arg-Lys-Lys-Arg↓Ser-Val-Ser-Glu-3-nitrotyrosine-Ser, where Abz is 2-aminobenzoic acid). 1 To whom correspondence should be addressed (e-mail abasak@ohri.ca).
PC2, PC4, PC5/6, PC7/8/LPC, furin/PACE (paired-basic-aminoacid-converting enzyme) and PACE4 [10, 11] , are synthesized as enzymically inactive zymogen forms that are also known as proenzymes. It has been demonstrated that the propeptide of subtilisin BPN , a bacterial model for the eukaryotic convertases, is involved and necessary for proper folding of subtilisin [12] , in addition to being a potent slow tight-binding inhibitor of the active enzyme [13] . Moreover, it has been shown that propeptide removal of kexin [14] , furin [15] and PC2 [16] is a prerequisite for enzyme activity and/or transport out of ER [14] . Elegant studies based on chimaeric molecules have shown that, in certain cases, the propeptide can be interchanged, such as with PC1/3 and furin [17] , leading to the correct expression of the recombinant enzymes. In other cases, such as proPC1/3 and proPC2, it is clearly not [15] . Studies with furin [18] , Kex-2 [19, 20] , PC1/3 [21] and PC7 [22] have provided strong evidence for the inhibitory role of the pro-region, although another study [23] has indicated that C-terminal region of PCs can also be inhibitory to the cognate enzyme. However, besides one study by NMR [24] , much of the mechanisms of action and the structural determinants of the proregion, and also the sites of binding involved in the observed potent inhibition remain to be established. Similarly, since cells are capable of expressing simultaneously a number of convertases, the question of specificity of each pro-region for its cognate enzyme remains unclear. In fact, studies indicated that prodomains of PCs do not display any high degree of inhibitory specificity towards the cognate enzymes [20] [21] [22] [25] [26] [27] [28] . The present study attempts to address some of these issues by defining important residues within the prosegment sequence, which are critical for enzyme inhibition. This is accomplished by studying the interaction of various synthetic peptides derived from the pro-regions of PC1/3 and furin with enzymically active PC1/3 and furin. The present paper describes in detail the design, synthesis, molecular characterization and comparative inhibitory properties towards PC1/3 and furin of a number of such synthetic peptides and some specific mutants. A preliminary account of a part of this study was reported earlier [26] .
MATERIALS AND METHODS
All fluoren-9-ylmethoxycarbonyl (Fmoc)-protected amino acid derivatives (L-form), coupling reagents and solvents for peptide synthesis were purchased from Applied Biosystems (Mississauga, Ont., Canada), Calbiochem. (San Diego, CA, U.S.A.), Armand Frappier Institute (Laval, Québec, Canada) and Richelieu Biotechnologies (Montréal, Québec, Canada). The fluorogenic substrate pyroglutamic acid (pGlu)-Arg-Thr-LysArg-4-methylcoumaryl-7-amide (MCA) was purchased from Peptides International (Louisville, KY, U.S.A.).
Peptide synthesis
Synthesis of all peptides were performed on an automated Applied Biosystems model 431A peptide synthesizer using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate ('HBTU')/N-hydroxybenzotriazole ('HOBT')-mediated FastMoc chemistry. In the case of sequence-related peptides, these were prepared by a single run of synthesis, removing part of the resin [p-hydroxymethylphenoxymethyl polystyrene ('HMP') resin] at the appropriate step and continuing the synthesis until the next desired length. The following sidechain-protecting groups were used: t-butyloxycarbonyl ('Boc') for Lys; 2,2,5,7,8-pentamethylchroman-6-sulphonyl (Pmc) for Arg; t-butyl for Ser, Thr, Asp and Tyr; and trityl for His, Asn and Gln. The synthesis was terminated before the removal of the N-terminal Fmoc-protecting group, which was finally removed following treatment with 20 % piperidine in Nmethylpyrrolidone. The bound peptides were then cleaved from the resin and fully deprotected by treatment for 3-4 h at room temperature with reagent K as described in [29] . In certain cases, due to the high content of protecting groups, particularly the Pmc of Arg residues, it was necessary to repeat the deprotection procedure for a second time.
Peptide purification and chemical characterization
The crude peptides were purified by reversed-phase HPLC (RP-HPLC) using a semi-preparative CSC Exsil C 18 (25 cm × 1.0 cm; Chromatography Speciality Co., St-Laurent, Québec, Canada) [29] . The buffer system consisted of an aqueous 0.1 % (v/v) trifluoroacetic acid solution and an organic phase of acetonitrile also containing 0.1 % (v/v) trifluoroacetic acid. The elution was carried out by using a linear gradient from 5 to 60 % organic phase in 60 min following a 5 min isocratic step at 5 % organic phase; the flow rate was adjusted to 2.0 ml/min. The separation was monitored by UV absorbance at 225 nm, whereas the inhibitory properties of selected chromatogram peaks were assayed by incubating an aliquot for 150 min and overnight with each enzyme in the presence of fluorogenic substrate. In all cases, the identified peptides were purified further under the same conditions using a CSC Exsil C 18 analytical column (25 cm × 0.46 cm) and a flow rate of 1.0 ml/min. The peptide purity and concentration were determined by quantitative amino acid analysis following 18-24 h hydrolysis in the presence of 5.7 M HCl in vacuo at 110
• C on a Beckman autoanalyser model 6300 with post-column ninhydrin detection system loaned to us generously by the Canadian National Research Council and coupled to a Varian DS604 integrator/plotter. The identity of each purified peptide was confirmed by mass-spectral analysis using either an MS-50 HMTCTA instrument operating in fastatom bombardment mode (University of Montréal, Québec, Canada) or a matrix-assisted laser-desorption ionization-timeof-flight (MALDI-TOF) Tofspec MicroMass instrument using 4-hydroxycinnamic acid as matrix (University of Waterloo, Ontario, Canada).
Peptide I, mouse PC1/3 (mPC1/3) (55-62): 8-mer, SerAla-Leu-His-Ile-Thr-Lys-Arg; RP-HPLC, R t = 28. • C. The material was then purified by RP-HPLC using a C 18 analytical column (Phenomenex) under the conditions described above. The collected peak (R t = 34.5 min) was lyophilized and characterized by MS and amino acid composition as IV ctdd (where ctdd is C-terminal double deletion) [mPC1/3 (50-81)] 32-mer, Arg-Arg-Ser-Arg-Arg-Ser-Ala-Leu-His-Ile-Thr-Lys-ArgLeu-Ser-Asp-Asp-Asp-Arg-Val-Thr-Trp-Ala-Glu-Gln-Gln-TyrGlu-Lys-Glu-Arg-Ser; MS, m/z 3975 (M + H)
+ and amino acid analysis Arg 6 
Recombinant enzymes
Initially the recombinant endoproteases human PC1/3 and hfurin were obtained from the secreted culture media of somatomammotroph GH 4 C 1 cells following infection with respective cDNAs encoding vaccinia viruses. The collected media were concentrated, dialysed and partially purified through anionexchange chromatography prior to use as described in [31] . In a later part of the study, the purified 71 kDa mPC1/3 form, obtained from medium following 36 h infection of Spodoptera frugiperda cells with Autographa californica nuclear polyhedrosis virusinfected cDNA of mPC1/3, was used [32] .
Enzymic assays and kinetic analysis
All in vitro enzymic assays were performed using either initial rate assays and/or end-time assays at room temperature in a final volume of 100 µl in 96-well flat-bottom white plates (Microfluor; Dynatec). For hfurin, the final assay conditions were 50 mM sodium acetate buffer, pH 7.0, in the presence of 1 mM CaCl 2 , whereas for mPC1/3 the conditions were 50 mM sodium acetate, pH 6.0, in the presence of 5 mM CaCl 2 . Unless stated otherwise, all assays were performed using a final concentration of 100 µM pGlu-Arg-Thr-Lys-Arg-MCA substrate. The release of the fluorescent 7-amino 4-methyl coumarin ('AMC') was quantified on line with a PerkinElmer model LS50B spectrofluorimeter using excitation and emission wavelengths of 370 + − 5 and 460 + − 3 nm respectively. For measurement of both K i (inhibition constant) and IC 50 (the concentration necessary to achieve 50 % inhibition of enzymic activity) values, the inhibitor concentrations were varied over a range wide enough to yield residual activities of 25-75 % of the control value. The various kinetic parameters were evaluated using Enzfitter software (Elsevier-Biosoft, Cambridge, U.K.). In the case of K i being derived from the IC 50 value, the following equation, applicable for reversible and competitive inhibitors, was used: [21, 32] and 5.9 µM for hfurin [33] respectively.
Determination of the K i using the internally quenched fluorogenic substrate QFS-8 (Abz-Gly-Ser-Arg-Lys-Lys-Arg↓Ser-ValSer-Glu-3-nitrotyrosine-Ser, where Abz is 2-aminobenzoic acid) [34] , derived from the sequence of the processing site of proparathyroid hormone (pro-PTH), was done essentially as described previously [34] .
Synthetic peptides as substrates of mPC1/3 and hfurin
Each of the peptides IV-VII (20 µg) was incubated separately at room temperature with enzymically active hfurin or mPC1/3 (5 µl) in 50 mM sodium acetate buffer (100 µl) containing 2 mM CaCl 2 at pH 7.0 for furin and 5 mM CaCl 2 at pH 6.0 for mPC1. Aliquots were withdrawn at intervals of 1 h until 4 h and analysed on RP-HPLC using the conditions as described above, in order to examine any possible proteolytic cleavage of the peptides.
RESULTS

Selection of the synthetic peptides
Extensive sequence alignment of the pro-regions of various convertases has shown that there exists limited amino acid conservation between each convertase. Indeed, for example, the similarity of sequences between the pro-region of furin and those of the other family members ranges from 29 % for PC7 to a maximum of 51 % for PC5/6 [35] . This similarity is much lower that observed within the catalytic domain, which ranges from a minimum of 54 % for PC2 up to 70 % for PC4. However, such an analytical procedure might not indicate the real story because, if one allows the introduction of gaps within each pro-region, a different picture emerges. In addition, conservation in PCs of certain amino acid residues can be seen as, for example, in the case of a Gly-Gly-Xaa 3 -Ala-Xaa 3 -Ala-Xaa 3 -Gly motif predicted to be a helical structure based upon Chou/Fasman and Garnier/Robson algorithms; this segment lies between positions 13 to 28 in proPC1/3. Similarly, it can be seen that in the C-terminal region of all proconvertases and hence preceding the proposed zymogenactivation site, a Val-Xaa-Trp-Xaa-Xaa-Gln-Gln-Xaa 4 -Arg-XaaLys-Arg↓ motif is strongly conserved, with the exception of the Trp being replaced in PC2. Also noteworthy is the presence of a His-Xaa-Xaa-His motif (where the Xaas are often aromatic and hydrophobic residues) near a putative secondary convertase cleavage site, Lys/Arg-Arg↓, occupying positions 50 and 51 in proPC1/3. Hence, in the present study, we have decided to focus on the last two above-mentioned motifs. This particular choice was further justified by the fact, as illustrated in Figure 1(A) , that both lie within surface-accessible and highly hydrophilic segments of the proPC1/3 region and by earlier studies of furin and PC7 [18, 21, 22] . Hence, peptides encompassing either of the two regions ( Figure 1B) were synthesized, namely peptides I-III, representing the region from residues 39 to 62, and peptides V-VII, representing residues 55-83. In addition, a longer peptide from residues 50 to 83 (peptide IV) was prepared together with three additional peptides spanning the first region as well as that found in the profurin region (peptides VIII-X). Moreover, two analogous mutant peptides, namely peptides IA and IIIA, were prepared by substituting the His residues for Ala to evaluate the contribution of the His residues. The rationale behind such mutation is based on our earlier observation that His-rich human salivary peptides that bear significant homology, including the conservation of all His residues of the prosegments, are inhibitors of PCs such as furin and PC7 [36] .
Synthetic peptides derived from the proPC1/3 or profurin residues 39-62
The important feature of region 39-62 is that it contains solely the secondary processing region, which is not considered as the cognitive putative site responsible for activation of the enzyme. As shown in Table 1 , these peptides, five in all with two His-to-Ala mutants, proved to be competitive inhibitors for either mPC1/3 or hfurin when assayed in the presence of the pGlu-Arg-ThrLys-Arg-MCA fluorogenic substrate. When examined against mPC1/3, all three synthetic peptides in the region 39-62, namely 55-62, 50-62 and 39-62, exhibited very close K i values, ranging The complete propeptide region of mPC1/3 (1-90) corresponds to residues 1-83. from 15 to 20 µM; substitution of all His residues in peptides I and III by Ala residues had a similar effect by slightly increasing the K i values. In the case of related profurin peptides in the same region, a slight increase in K i values was observed, with values ranging from 10 to 70 µM. However, when examined against the enzymic activity of hfurin, the results were quite different, inasmuch as much lower K i values were obtained with both proPC1/3 and profurin-related peptides. Indeed, as can be seen in the case of the longer peptide (Table 1) , values in the nanomolar range were obtained. Thus for example, using pGlu-Arg-ThrLys-Arg-MCA as the substrate, promPC1/3 (39-62) displayed for hfurin a K i value of 700 nM, which is 22-fold more potent than that for mPC1/3 ( Figure 2A ). These data indicated a lack of specificity for inhibition of cognate enzyme by its own prodomain derived synthetic peptides. Similar observation was also noted previously [21, 22] . However, the same peptide inhibited furin activity more strongly (K i = 350 nM, Figure 2B ) when measured against a pro-PTH-derived intramolecularly quenched fluorogenic substrate, QFS-8 [34] , which unlike the peptidyl-MCA substrate contains both P and P residues. QFS-8 is a much better substrate (K m = 3 µM) than pGlu-Arg-Thr-Lys-Arg-MCA (K m = 20 µM).
Interestingly, substitution of the His residues by Ala had only marginal effect on the inhibition of enzymic activity of furin ( Table 1) , suggesting that at least in these peptides His residues do not seem to play any critical role towards their furin inhibitory property.
Synthetic peptides related to the proPC1/3 residues 64-83
The peptides derived from the region 64-83 all contain the important primary processing site [with P-residues (Scheeter and Berger's nomenclature) alone] responsible for release of the active enzyme. These peptides, numbered V-VII, exhibited upon incubation with mPC1/3 at least a 10-fold reduction in K i values when compared with other peptides mentioned above, yielding values in the 1-2 µM range (Table 1) . Interestingly, even the shortest peptide, VII, when assayed with hfurin exhibited nearly a 25-fold increase in K i value compared with that against mPC1/3. This observation is noteworthy because of the fact that there is a high degree of sequence similarity between proPC1/3 and profurin in this region, with six residues out of 10 being identical. However, given the fact that the
Table 1 Apparent inhibition constant (K i ) of various proPC1/3-and profurin-related peptides
The basic residues at the primary and secondary processing sites are indicated in bold and underlined respectively. The His-to-Ala mutations are indicated in italics. ND, not determined. † Determined using the internally quenched fluorogenic substrate QFS-8 derived from the pro-PTH sequence [34] (see the Materials and methods section). ‡ K i values for mixed-type inhibition. § Values were taken from our previous study [22] . furin substrate-recognition cleft has been proposed to contain a very high number of acidic residues [37, 38] , the presence of two unfavourable Glu residues occupying positions P7 and P5 (Schechter and Berger's nomenclature of substrate positions) in peptide VII may explain this significant fall in potency for furin inhibition.
It was also noted that pro-mPC1/3 (55-83) is a more potent PC1/3 inhibitor (K i = 0.3 µM) than pro-mPC1/3 (64-83) (K i = 0.6 µM), which is again a stronger inhibitor than pro-mPC1/3 (74-83) (K i = 0.89 µM; Table 1 ). This seems to suggest that elongation of the peptide chain towards the N-terminus direction from the putative site leads to more potent inhibition of PC1/3. However, further elongation, as noticed with peptide IV, led to a small decrease but a different mode of inhibition (see the following section) in the potency of PC1/3 inhibition, suggesting an optimum sequence for best interaction.
Type of enzyme inhibition
A previous study reported that a polypeptide containing the entire prosegment sequence of PC1/3 plus an additional 14 amino acid residues beyond the zymogen-activation site, i.e. segment 1-98, exhibited extremely potent but slow tight-binding inhibition with K i = 6 + − 0.6 nM against mPC1 and 10 + − 1.0 nM against hfurin [21] . Whereas none of the synthetic peptides exhibited enzyme inhibition potency as strong as this 98-amino-acid peptide, promPC1/3 (39-62) and prohfurin (39-62), both of which contain only the secondary processing site, were however the two most potent furin inhibitors in this study. Both these synthetic peptides, like most others examined, exhibited truly competitive inhibition. This is demonstrated by the linearity of the progress curves, as shown in Figure 3 , as a model example for the inhibition of mPC1/3 activity by promPC1/3 (74-83) (peptide VII). This Progress curves were obtained using 100 µM pGlu-Arg-Thr-Lys-Arg-MCA in the presence of increasing concentrations of the purified peptide, as indicated, from 0 (top curve) to 6.6 µM (bottom curve). The amount of peptide used was measured following amino acid analysis using norleucine as an internal standard and the peptide was added to the enzyme solution at the same time as the fluorogenic substrate in a total volume of 100 µl in a 96-well plate. conclusion is further reinforced by examining the Dixon and Woolf or Hanes plots, shown in Figure 4 , for the inhibition of mPC1/3 activity by promPC1/3 (74-83) peptide. The converging linear curves observed in Dixon plot ( Figure 4A ) and the near parallel lines seen in Woolf or Hanes plot ( Figure 4B ) are typical for true competitive inhibition. However, not all inhibitions are of an identical nature, as exemplified by deviations from the above observations (results not shown). For example, whereas the short C-terminal peptide pro-mPC1/3 (74-83) is a fully competitive inhibitor of PC1, the two longer pro-mPC1 (64-83) and promPC1/3 (55-83) peptides were both mixed-type inhibitors of PC1/3 (results not shown). This indicates that, unlike the short peptide which interacts only at the catalytic site of PC1/3, the two larger peptides provide additional interactions at sites remote from the active site of the enzyme. Interestingly, the even larger promPC1/3 (50-83) peptide behaves as a non-competitive inhibitor. Thus besides interacting with the catalytic residues, some peptide inhibitors can also interact with the non-catalytic domain of the enzyme thereby modifying its activity. In fact the prodomains of several convertases such as kexin and PC7 were shown to behave as mixed-type inhibitors of the cognate enzymes [20, 22, 36] .
A comparative analysis of the inhibitory profile towards the proteolytic activity of mPC1 of three synthetic pro-mPC1/3-derived peptides, namely peptides IV (50-83), V (55-83) and VI (64-83), seems to suggest that the maximum PC1-inhibitory property is located within the 50-83 segment of the promPC1/3 sequence. It may be pointed out that despite the presence of potential PC-cleavage sites in some of these peptides, such as peptides IV-VII, none of them in fact were cleaved to any significant extent (within a detection limit of 2-3 %) by the proteolytic action of either mPC1/3 or hfurin under the experimental conditions employed for the inhibition studies. This observation confirms the notion that these synthetic peptides behave mostly as true inhibitors and not as competitive substrates.
Carboxypeptidase E treatment of promPC1/3 (50-83) and its effect on the PC inhibitory property CD studies of peptide IV [promPC1/3 (50-83)], one of the most potent PC1/3 inhibitors in this study, and some related peptides demonstrated important differences in their secondary structures, e.g. α-helix, β-strand and turn contents (results not shown). This and previous observations [21, 22] prompted us to investigate the role of the two (P1-P2) C-terminal basic residues (Lys 82 -Arg 83 ) in enzyme-inhibitory property exemplified by the peptides containing such residues, e.g. peptide IV [pro-mPC1/3 (50-83)]. In order to accomplish this objective, peptide IV was treated with carboxypeptidase E as described in the Materials and methods section. The resulting peptide digest was purified by RP-HPLC ( Figure 5 ) and then subjected to mass-spectral analysis. As shown in Figure 6 , the MALDI-TOF MS of purified carboxypeptidase E-treated peptide IV peak eluted at R t = 34.8 min (
Figure 5B) exhibited a major peak at m/z 3975, compared with the peak at m/z 4258 displayed by the parent peptide peak eluted at R t = 35.5 min ( Figure 5A ). This represented a decrease of 284 mass units corresponding to the two C-terminal Lys-Arg residues, suggesting that upon treatment with carboxypeptidase E the peptide IV loses its C-terminal pair of basic residues (Lys-Arg), yielding the peptide pro-mPC1 (50-81). This was further confirmed by amino acid analysis (see the Materials and methods section). The above two peptides were then tested in parallel for their mPC1/3 inhibitory activity. Interestingly, as shown in Figure 7 , the carboxypeptidase E-treated peptide, pro-mPC1/3 (50-81), lost significantly its ability to inactivate mPC1/3 compared with the parent peptide pro-mPC1/3 (50-83). This demonstrated clearly a critical role in enzyme inhibition of the terminal basic residues Progress curves were obtained using 100 µM pGlu-Arg-Thr-Lys-Arg-MCA in the absence or presence of 5.8 µM of either pro-mPC1 (50-83) or pro-mPC1/3 (50-81). The latter peptide was obtained following carboxypeptidase E treatment of promPC1/3 (50-83) and purification by RP-HPLC as described in the Materials and methods section. The slope of each curve is represented by the accompanying dotted line. The two nearly overlapping curves at the top represent the progress curves for PC1/3 activity in the presence (black) and absence (grey) of peptide as indicated. The loss of PC1/3-inhibitory activity of the des-Lys-Arg peptide is clearly noticeable. The exact concentration of each peptide used was evaluated by amino acid analysis. similar conditions inhibited only 0.8 + − 0.25 % of the activity, indicating a difference of at least of 80-fold in mPC1/3-inhibitory property between the two peptides ( Table 2) .
DISCUSSION
The present study revealed that certain regions of prosegments of both mPC1 and hfurin possess modest to high degrees of enzyme-inhibitory ability against their cognate enzymes, mPC1/3 and hfurin. Based on studies involving a number of peptides located at different regions of the propeptide, the highest mPC1/3 inhibitory property was located within segment 50-83 of the promPC1/3 sequence, representing the N-terminal sequence preceding the primary activation site Lys-Glu-Arg-Ser-Lys-Arg 83 ↓. This suggests a highest degree of interaction of this segment with the various subsites representing the catalytic site of the enzyme. Interestingly, this region is characterized by the presence of α-helix at the N-terminus followed immediately by an exposed hydrophobic β-strand structure [39] . The presence of this structural motif may be crucial for the observed inhibition of PC1/3-activity. On the contrary, the most potent hfurin-inhibitory property in this study was located within the peptide sequence 39-62 of both promPC1/3 and prohfurin, which contains the secondary processing site alone (K i = 700-900 nM) and characterized by the presence of a highly exposed β-strand structure at the N-terminus followed by a loop structure [39] . However, in an earlier study [22] we have already shown that hfurin (74-83) (referred as hFur-C10; QQVAKRRTKR↓) and (60-83) (referred as hfur-C24; HSRLQREPQVQWLWQQVAKRRTKR↓), both of which contain only the zymogen-activation site, inhibited furin with a much higher degree of potency (K i ranging from 35 to 40 nM), confirming again the importance of a primary activation site in furin inhibition as well. This and other studies [21, 22, 26] support the notion that the presence of primary and/or secondary processing sites in the prosegment-derived peptide enhances significantly the protease-inhibitory property. Furthermore, our data also revealed that contrary to the entire prosegment polypeptide [21, 22] , the small-sized synthetic peptides did not show any significant selectivity in enzyme inhibition within various members of the PC family tested so far. However, it is necessary to examine the behaviours of these peptides against the activity of all members of the PC familys before such a conclusion can be established firmly. The dramatic loss of the mPC1/3-inhibitory property of promPC1/3 (50-83) peptide following treatment with carboxypeptidase E indicated clearly the critical role in enzyme inhibition of Lys 82 -Arg 83 residues located at the primary cleavage site. Previously the critical role of P1 Arg in inhibition of convertase activity had been demonstrated by mutational studies [21, 22] . Our data with mutant peptides (Ala for His) did not reveal any significant roles of His residues in enzyme inhibition by these peptides. The study confirmed further that small-to-medium-sized synthetic peptides derived from prosegments of PCs are able to display modest to relatively potent PC-inhibitory ability, mostly in a competitive manner. However, none of the synthetic peptides reported in this study exhibited a slow tight-binding inhibition as displayed by the full-length propeptides of furin, PC1/3 and PC7 [21, 22] . This suggested that the various subsites of the active enzymes are large enough to interact with the whole propeptide in a more effective manner compared with the relatively small peptides. This is particularly valid in light of the reported theoretical modelling structures of furin [37, 38] and PC1/3 [40] . Further studies, including mutagenesis and secondary structure analysis using NMR and CD techniques that are currently in progress, are required to better understand molecular mechanisms involved in the pro-region binding to their cognate enzymes and to determine more precisely the nature of the residues involved in the inhibition process.
